KEGG   DRUG: Cladribine
Entry
D01370                      Drug                                   
Name
Cladribine (JAN/USP/INN);
Leustatin (TN);
Mavenclad (TN)
Product
  Generic
Formula
C10H12ClN5O3
Exact mass
285.0629
Mol weight
285.687
Structure
Simcomp
Class
Antineoplastic
 DG02018  Antimetabolite
  DG01958  Nucleic acid derivative, antineoplastic
Remark
Therapeutic category: 4291
ATC code: L01BB04 L04AA40
Product: D01370<JP/US>
Efficacy
Antineoplastic, Antimetabolite
  Disease
Hairy-cell leukemia [DS:H00006]
Multiple sclerosis [DS:H01490]
Target
RRM1 [HSA:6240] [KO:K10807]
DNA polymerase
  Pathway
hsa00230  Purine metabolism
hsa00240  Pyrimidine metabolism
Interaction
Structure map
map07041  Antineoplastics - antimetabolic agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01B ANTIMETABOLITES
    L01BB Purine analogues
     L01BB04 Cladribine
      D01370  Cladribine (JAN/USP/INN) <JP/US>
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA40 Cladribine
      D01370  Cladribine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antimetabolites
   Cladribine
    D01370  Cladribine (JAN/USP/INN)
 Central Nervous System Agents
  Multiple Sclerosis Agents
   Cladribine
    D01370  Cladribine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D01370  Cladribine (JAN/USP/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG02018  Antimetabolite
   DG01958  Nucleic acid derivative, antineoplastic
    D01370  Cladribine
Drug classes [BR:br08332]
 Antineoplastic
  DG02018  Antimetabolite
   D01370  Cladribine
Target-based classification of drugs [BR:br08310]
 Enzymes
  Oxidoreductases (EC1)
   Ribonucleoside-diphosphate reductase
    RRM1
     D01370  Cladribine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D01370
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D01370
Other DBs
CAS: 4291-63-8
PubChem: 7848433
ChEBI: 567361
PDB-CCD: CL9[PDBj]
LigandBox: D01370
NIKKAJI: J446.344G
KCF data

ATOM        19
            1   C1y C    13.2977  -19.5392
            2   C1x C    14.6838  -19.5392
            3   C1y C    15.1121  -18.2209
            4   O2x O    13.9907  -17.4062
            5   C1y C    12.8694  -18.2209
            6   N5x N    17.5130  -19.6070
            7   C8y C    17.5130  -18.2209
            8   N4y N    16.3126  -17.5278
            9   C1b C    11.6689  -17.5278
            10  O1a O    10.4685  -18.2209
            11  O1a O    12.4829  -20.6606
            12  C8y C    18.7133  -20.3000
            13  N5x N    19.9138  -19.6070
            14  C8y C    19.9138  -18.2209
            15  C8y C    18.7133  -17.5278
            16  C8x C    16.7284  -16.1436
            17  N5x N    18.2975  -16.1432
            18  X   Cl   18.7133  -21.6877
            19  N1a N    21.1159  -17.5266
BOND        21
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     1   5 1
            6     6   7 1
            7     7   8 1
            8     3   8 1 #Up
            9     5   9 1 #Up
            10    9  10 1
            11    1  11 1 #Down
            12    6  12 2
            13   12  13 1
            14   13  14 2
            15   14  15 1
            16    7  15 2
            17    8  16 1
            18   15  17 1
            19   16  17 2
            20   12  18 1
            21   14  19 1

» Japanese version   » Back

DBGET integrated database retrieval system